Paul Kerr

7 results

Belfast research contract group Fusion Antibodies reported record second-half revenues as it moves past AIM-listing pressures.

Northern Ireland contract research company Fusion Antibodies recorded a 19 per cent fall in full year revenues to £2.2 million on the back of a weak f(...)

Paul Kerr, chief executive of Fusion Antibodies.

Northern Ireland contract research company Fusion Antibodies warned that revenues for the year ended March 31st would be “materially below current mar(...)

Fusion Antibodies CEO Paul Kerr said it had been a challenging period but   company had ‘turned a corner’.

Losses at Belfast pharmaceutical company Fusion Antibodies quadrupled in the six months ended September 30th compared with the same period last year, (...)

Fusion Antibodies has a particular focus on the production of antibodies in a lab. Photograph: iStock

Fusion Antibodies, the Northern Ireland contract research company, has reported losses of nearly £700,000 (€781,000) for its maiden year as an AIM-lis(...)

Fusion Antibodies placed 6,707,317 ordinary shares on AIM at a price of £0.82

Belfast pharma company Fusion Antibodies has raised £5.5 million (€6.2m) in its debut on the junior market of the London Stock Exchange. Fusion, a c(...)

RBAI’s Rhys O’Donnell scores his side’s  try. Photograph: Brian Little/Inpho
RBAI dig deep to deny Methody
  • Rugby
  • March 17, 2017, 17:25

RBAI 12 Methodist College 8 Holders Royal Belfast Academical Institution secured a hat-trick of Danske Bank Ulster Schools’ Cup titles in what was a (...)

Embo Medical (from left) Wayne Allen, Colin Forde and Liam Mullins. The firm was voted “one-to watch” by the CorkBIC Venture Academy.

Embo Medical Embo Medical has created a new medical device which makes embolization procedures faster and less expensive while also offering mo(...)